Incorrect password
evipedia.ai Suggest Edit

L-Citrulline for Health & Longevity

Evidence Review created on 04/27/2026 using AI4L / Opus 4.7

Also known as: Citrulline, Cit, 2-amino-5-(carbamoylamino)pentanoic acid, Citrulline Malate

Motivation

L-Citrulline is a non-protein amino acid that the body uses as a precursor to L-arginine and, downstream, to nitric oxide. It is found naturally in watermelon (from which it takes its name) and is produced internally during the urea cycle. Unlike oral L-arginine, which is heavily broken down in the gut and liver, oral L-Citrulline survives that first pass and reliably raises plasma arginine.

Interest in supplementation centers on three areas: modest reductions in resting blood pressure, support for vascular function and exercise performance through enhanced nitric oxide signaling, and a small body of work on erection quality. Watermelon-derived citrulline has been studied alongside the purified amino acid since the early 2000s, and citrulline is now a standard ingredient in pre-workout formulations.

This review examines what controlled evidence supports for L-Citrulline in health- and longevity-oriented adults, considers where mechanism-driven enthusiasm outpaces clinical data, and lays out which interactions and population-specific cautions matter most for those weighing supplementation.

Benefits - Risks - Protocol - Conclusion

This section curates high-level expert content offering accessible overviews of L-Citrulline for blood flow, blood pressure, and exercise applications.

  • Nootropics for Athletes: Citrulline, Beetroot Juice & Alpha-GPC - Josh May

    A third-party written summary of the Andy Galpin / Andrew Huberman discussion on the Huberman Lab podcast covering L-Citrulline as a nitric oxide precursor for athletic performance, including the rationale for the pre-workout dose, the comparative advantage over oral L-arginine due to first-pass metabolism, and the explicit caution that L-Citrulline can trigger cold sores or canker sores in susceptible individuals carrying herpes simplex virus type 1.

  • Nitric Oxide and Cardiovascular Health - Michael Downey

    A practitioner-oriented Life Extension Magazine overview that frames endothelial nitric oxide decline as a central feature of vascular aging, summarizes the L-arginine and L-Citrulline precursor pathway, and outlines why supplementation strategies (including stabilized arginine silicate forms) are used in cardiovascular support protocols.

  • l-Citrulline Supplementation: Impact on Cardiometabolic Health - Allerton et al., 2018

    A widely cited narrative review in Nutrients covering L-Citrulline’s biochemistry, the pharmacokinetic advantage over oral L-arginine, dose–plasma arginine response, and the cardiometabolic contexts in which citrulline has been investigated, from cardiovascular risk to exercise to inherited urea cycle disorders.

Note: Only 3 high-quality eligible items could be located. Peter Attia has no standalone treatment of L-Citrulline on peterattiamd.com despite searching the site directly; references to citrulline appear only in passing within broader supplement and blood pressure content. Rhonda Patrick’s coverage on FoundMyFitness occurs primarily within episodes (e.g., the Andy Galpin discussion of pre-workout ergogenic aids) and AMA segments rather than as a standalone, freely accessible article. Chris Kresser’s blog likewise has no dedicated article on L-Citrulline; his blood pressure pieces focus on other supplement strategies (CoQ10, garlic, magnesium, vitamin C, potassium) without addressing citrulline. Other expert blogs cover citrulline only briefly within broader nitric oxide discussions, and the most-cited dedicated literature consists of systematic reviews and meta-analyses, which belong in the Systematic Reviews section per the section guidelines.

Grokipedia

Citrulline

A comprehensive biochemistry-oriented entry covering citrulline’s structure, its role as a urea cycle intermediate and L-arginine precursor, the discovery in watermelon by Koga and Ohtake in 1914, oral pharmacokinetics with conversion in the kidneys, and current evidence for nutraceutical applications in cardiovascular support, exercise performance, and erectile function.

Examine

Citrulline - Health benefits, dosage, safety, side-effects, and more

Examine.com’s structured monograph aggregates clinical evidence on L-Citrulline (and citrulline malate) across muscle gain, exercise performance, blood pressure, and erectile dysfunction outcomes, with grading on each outcome, a frequently asked questions section, and detailed safety notes and interactions.

ConsumerLab

L-Citrulline Supplements Review

ConsumerLab’s review covers product testing for label accuracy and heavy metal contamination, identifies Top Picks for L-Citrulline in both powder and capsule formats, summarizes clinical evidence as showing only modest to no benefit for exercise performance and cardiovascular use (with one small study supporting mild erectile dysfunction), and provides specific safety guidance regarding co-administration with antihypertensive medications.

Systematic Reviews

This section presents the most relevant systematic reviews and meta-analyses of L-Citrulline identified through PubMed.

Mechanism of Action

L-Citrulline acts primarily as a precursor amino acid feeding the L-arginine–nitric oxide (NO) pathway, with downstream effects on vascular tone, blood flow, and nutrient delivery to tissues.

Conversion to L-arginine. Oral L-Citrulline is absorbed intact in the small intestine via amino acid transporters and largely escapes first-pass metabolism, reaching the systemic circulation. In the proximal renal tubule, the enzymes argininosuccinate synthetase (ASS, the rate-limiting enzyme that condenses citrulline and aspartate to form argininosuccinate) and argininosuccinate lyase (ASL, the enzyme that splits argininosuccinate into L-arginine and fumarate) convert L-Citrulline to L-arginine. Plasma L-arginine peaks roughly 1 hour after an oral L-Citrulline dose, in a dose-dependent fashion. Critically, this route bypasses the intestinal and hepatic arginase activity that degrades a large fraction of orally administered L-arginine itself — making L-Citrulline a more efficient way to raise systemic arginine than L-arginine itself.

Nitric oxide synthesis. L-arginine is the substrate for the three isoforms of nitric oxide synthase (NOS): endothelial NOS (eNOS, the vascular isoform whose product relaxes blood vessels), neuronal NOS (nNOS), and inducible NOS (iNOS, expressed in immune cells under inflammation). Each NOS isoform catalyzes the conversion of L-arginine to nitric oxide and citrulline (regenerated). NO diffuses into vascular smooth muscle and activates soluble guanylate cyclase, which produces cyclic guanosine monophosphate (cGMP, the second messenger that relaxes smooth muscle and dilates vessels). The end result is improved endothelium-dependent vasodilation, lower vascular resistance, and increased blood flow.

Urea cycle and ammonia handling. L-Citrulline is also a urea cycle intermediate. In hepatocytes, ornithine and carbamoyl phosphate are condensed by ornithine transcarbamylase (OTC) to form citrulline, which then proceeds through ASS and ASL to ultimately produce urea (the body’s main route for excreting ammonia). Citrulline supplementation may modestly support ammonia clearance in some clinical scenarios — and this is the basis for its therapeutic use in inherited urea cycle disorders. Conversely, in disorders where citrulline accumulates upstream (e.g., citrullinemia type I from ASS deficiency), supplementation is contraindicated.

Pharmacokinetics. Oral L-Citrulline is absorbed via amino acid transporters with bioavailability that exceeds that of oral L-arginine for raising systemic arginine. Plasma citrulline rises within 30–60 minutes; downstream L-arginine peaks at approximately 1 hour, in a dose-dependent fashion. The terminal half-life is short (citrulline itself is rapidly cleared), but the secondary L-arginine elevation persists for several hours and outlasts the comparable response to oral L-arginine. Renal conversion (rather than hepatic clearance) is the principal metabolic step. Cytochrome P450 (CYP) metabolism is not relevant. A typical 3-g dose roughly doubles plasma L-arginine within 1 hour; 6-g and higher doses produce larger and more sustained elevations.

Selectivity and tissue distribution. L-Citrulline distributes to plasma and is converted preferentially in renal tissue. Effects are systemic — there is no selectivity for any specific vascular bed beyond the inherent distribution of NOS isoforms. The signaling output therefore depends on baseline endothelial function: in adults with well-functioning endothelium (younger, low cardiovascular risk), the marginal NO contribution may be small; in adults with endothelial dysfunction (older, hypertensive, hypercholesterolemic), the substrate-limited supply curve makes the same dose more impactful.

Where mechanisms compete. Two factors blunt the simple “more substrate → more nitric oxide” model. First, asymmetric dimethylarginine (ADMA, an endogenous NOS inhibitor whose levels rise with cardiovascular risk and aging) competes with L-arginine at the NOS active site; raising L-arginine via citrulline can shift this ratio favorably. Second, in highly trained or healthy individuals, eNOS function may already be near-maximal and additional substrate produces little marginal benefit — which is the standard explanation for the heterogeneous and often null results in young athletic populations versus the more consistent signals in middle-aged and older adults with endothelial dysfunction.

Historical Context & Evolution

L-Citrulline was first isolated in 1914 by Japanese researchers Koga and Ohtake from the juice of watermelon (Citrullus vulgaris), and the name derives from the Latin citrullus — watermelon. Its role in the urea cycle was established by Hans Krebs and Kurt Henseleit in 1932 as part of their seminal description of mammalian ammonia detoxification, placing citrulline alongside ornithine and arginine as core intermediates of nitrogen metabolism.

For most of the twentieth century, citrulline was studied primarily as a metabolic intermediate, an enterocyte-mass biomarker, and as a treatment adjunct for inherited urea cycle disorders such as ornithine transcarbamylase deficiency. Its use as a nutraceutical for cardiovascular and exercise applications is largely a development of the late 1990s and 2000s, when several lines of work converged: pharmacokinetic studies established that oral L-Citrulline raises plasma L-arginine more efficiently than oral L-arginine itself; small clinical trials in mild erectile dysfunction (notably the Cormio 2011 single-blind trial in Italy) reported benefits; and citrulline malate — a 1:1 salt of citrulline with malic acid originally marketed in France as Stimol for asthenia (a state of physical or mental fatigue) — entered the pre-workout supplement market.

Since the mid-2010s, the field has produced a steady stream of small RCTs and several systematic reviews. The picture that has emerged is consistent: L-Citrulline produces small but reproducible reductions in resting blood pressure (approximately −4 mmHg systolic, −2.5 mmHg diastolic in older adults per the 2025 Luo meta-analysis) and small effects on resistance-exercise repetitions and post-exercise perceived exertion (per the 2019 Trexler and 2020 Rhim meta-analyses), with no consistent benefit in young-adult endurance trials (per the 2022 Viribay and 2023 Harnden meta-analyses). The 2018 retraction of an earlier blood pressure meta-analysis (Mahboobi et al., later retracted by Journal of Human Hypertension) underscores the importance of weighting more recent, methodologically careful syntheses. In parallel, basic-science work on the L-arginine/ADMA ratio, endothelial dysfunction, and aging has placed citrulline within a broader vascular-aging biology framework where it serves as one of several substrate strategies for supporting nitric oxide signaling alongside dietary nitrate (beetroot), polyphenols, and exercise.

Expected Benefits

A dedicated search for L-Citrulline’s complete benefit profile was conducted across systematic reviews, narrative reviews, integrative-medicine sources, and the vascular-aging literature prior to drafting this section.

Medium 🟩 🟩

Reduction in Resting Blood Pressure in Middle-Aged and Older Adults

L-Citrulline supplementation produces small but reproducible reductions in resting systolic and diastolic blood pressure, particularly in middle-aged and older adults. The 2025 Luo et al. meta-analysis of 15 RCTs (24 datasets, 415 participants) found a weighted mean reduction of −4.02 mmHg systolic and −2.54 mmHg diastolic with L-Citrulline supplementation or watermelon intake. The proposed mechanism is increased L-arginine availability for endothelial NO synthesis, leading to vasodilation and lower vascular resistance. Subgroup analyses suggest combined L-Citrulline plus L-arginine produces larger reductions (~−10 / −5 mmHg) than either alone, although these subgroup estimates rest on fewer trials.

Magnitude: −4.02 mmHg systolic (95% CI −6.54 to −1.50) and −2.54 mmHg diastolic (95% CI −4.27 to −0.81) in older adults at typical doses of 3–6 g/day for 4–8 weeks.

Improvement in Erection Hardness in Mild Erectile Dysfunction

In men with mild erectile dysfunction (ED), oral L-Citrulline at 1.5 g/day for 1 month improved subjective erection hardness scores. The 2011 Cormio single-blind trial of 24 men reported that 50% of participants improved from “mild ED” to “normal erectile function” on L-Citrulline versus 8% on placebo (P < .01), with mean monthly intercourses increasing from 1.5 to 2.3. The mechanism is straightforward: L-Citrulline raises L-arginine availability for NOS in penile tissue, supporting the same NO–cGMP axis that phosphodiesterase type 5 (PDE5, the enzyme that breaks down cGMP and is inhibited by sildenafil and similar drugs) inhibitors target. Effect size is smaller than that of PDE5 inhibitors but the safety profile is favorable.

Magnitude: Improvement to “normal” erectile function in 50% of users versus 8% on placebo at 1.5 g/day in mild ED; smaller effect than PDE5 inhibitors.

Low 🟩

Reduction in Post-Exercise Muscle Soreness and Perceived Exertion

Acute L-Citrulline (most often given as 8 g of citrulline malate ~1 hour pre-exercise) reduces self-reported RPE and muscle soreness at 24 hours after resistance or high-intensity exercise. The 2020 Rhim meta-analysis of 13 RCTs (n=206) reported significant pooled effects on RPE (P=0.03) and 24-hour muscle soreness (P=0.04), with no consistent effect on blood lactate. Effects do not extend reliably to 72-hour soreness.

Magnitude: Statistically significant pooled reductions in RPE and 24-hour muscle soreness; small-to-moderate effect sizes in trial-level data.

Small Effect on Acute Strength and Power Performance ⚠️ Conflicted

Single doses of L-Citrulline (≥3 g, 30+ minutes pre-exercise) produce a small but statistically significant pooled improvement in strength and power output across 12 studies (Trexler 2019 meta-analysis: Hedges’ g 0.20, 95% CI 0.01–0.39). However, individual-trial confidence intervals cross the null and the effect is inconsistent across populations and tasks. The 2021 Vårvik meta-analysis of citrulline malate found a similar small effect on resistance-training repetitions. Effect sizes are sufficiently small that day-to-day variability often masks them outside elite-athlete contexts.

Magnitude: Hedges’ g ≈ 0.20 (small effect) on strength and power; clinically meaningful primarily in elite-margin contexts.

Improved Exercise Blood Flow in Older Men

Chronic L-Citrulline supplementation has been shown to increase femoral arterial blood flow (~11%) and vascular conductance (~14%) during submaximal lower-limb exercise in older men, in small mechanistic studies. The signal is less consistent in older women, in young trained men, and at rest, and has not translated reliably to better endurance performance. Relevance is primarily mechanistic — confirming the L-arginine/NO pathway in older endothelial-dysfunction populations rather than yielding an applied performance benefit.

Magnitude: ~11% increase in femoral blood flow during submaximal exercise in older men in small RCTs; not consistent across populations.

Modest Improvement in Body Composition with Combined Exercise (Older Adults)

The 2023 Xie et al. meta-analysis of older adults combining citrulline supplementation with exercise found modest improvements in lean body mass and lower-limb function compared with exercise alone, in a small number of trials. Mechanism is unclear but presumed to involve improved blood flow and amino acid delivery during training. Effect is modest and conditional on simultaneous exercise.

Magnitude: Small pooled effect on lean mass and lower-limb function in 4–6 trials of older adults (e.g., 60+ years) combining citrulline with structured exercise.

Speculative 🟨

Vascular Aging and “Inflammaging” Modulation

Endothelial NO production declines with age, and the L-arginine/ADMA ratio worsens. Whether long-term L-Citrulline supplementation alters the trajectory of vascular aging or downstream cardiovascular events is not established in interventional trials. Mechanistic plausibility is real; clinical demonstration is absent.

Adjunct in Heart Failure with Preserved Ejection Fraction (HFpEF)

The currently recruiting NCT06312748 trial is testing L-Citrulline as part of a multi-arm intervention for vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF, a form of heart failure where the heart pumps normally but has trouble relaxing and filling). No completed phase 3 evidence supports a benefit; the rationale is the well-documented endothelial-dysfunction phenotype of HFpEF.

Pre-Eclampsia Prevention

A large body of L-arginine evidence suggests reduced pre-eclampsia risk in prevention trials, but only one small trial has evaluated L-Citrulline specifically and found no effect (Makama 2025 meta-analysis). The recruiting AGREE trial (NCT05934318) of 2,960 pregnant Kenyan women may resolve this question. Until completion, L-Citrulline–specific evidence in pregnancy is preliminary and the default position is L-arginine if a precursor is being considered, under medical supervision.

Sickle Cell Vaso-Occlusive Pain

Intravenous L-Citrulline is being studied (NCT06635902) for acute vaso-occlusive pain crises in sickle cell disease, on the rationale that arginine depletion is a feature of the disease. This is a clinical-population indication, not relevant to general health and longevity use.

Lifespan Extension (C. elegans)

L-Citrulline has been shown to extend lifespan in Caenorhabditis elegans in a small number of laboratory studies. No mammalian lifespan or healthspan trial has been completed; relevance to human longevity is theoretical only.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in eNOS (e.g., the Glu298Asp polymorphism, which alters endothelial NO synthase activity) and in DDAH1/DDAH2 (the enzymes that degrade ADMA) may influence the magnitude of the NO response to substrate provision. Variants in arginase isoforms (ARG1, ARG2) can shift baseline arginine availability. Routine genotyping is not standard, but these variants help explain inter-individual variability in blood pressure response.

  • Endothelial function and ADMA status: Adults with endothelial dysfunction (older, hypertensive, hypercholesterolemic, diabetic) and elevated asymmetric dimethylarginine (ADMA) — an endogenous NOS inhibitor — show larger blood pressure and blood flow responses than younger, low-risk adults. The L-arginine/ADMA ratio is the most relevant single biomarker.

  • Baseline blood pressure: Larger reductions occur in those with elevated baseline systolic blood pressure (e.g., >130 mmHg) than in those with normal blood pressure; this matches the 2025 Luo meta-analysis subgroup pattern.

  • Baseline plasma L-arginine: Adults with low baseline L-arginine or low arginine-to-ADMA ratio respond more — the substrate-supply curve is steeper when supply is limiting.

  • Sex differences: Some exercise blood-flow studies have shown effects in older men but not in older women, suggesting sex-specific response patterns possibly mediated by estrogen-related differences in eNOS function. Most blood-pressure trials have been mixed-sex without formal sex stratification.

  • Pre-existing health conditions: Cardiovascular conditions associated with endothelial dysfunction (hypertension, type 2 diabetes, peripheral artery disease, HFpEF) tend to predict greater response. Conversely, well-controlled, low-risk individuals show smaller effects.

  • Age-related considerations: Older adults (≥60) show greater blood pressure responses and may show greater functional benefits when citrulline is combined with exercise; the same dose is unlikely to produce a comparable signal in healthy young adults.

  • Inflammatory state: Chronic inflammation increases ADMA and reduces eNOS coupling. Adults with high baseline C-reactive protein (CRP) or other inflammatory markers may respond differently — sometimes more (because the substrate gap is larger), sometimes less (because eNOS is uncoupled).

  • Concurrent dietary nitrate intake: A diet rich in dietary nitrate (leafy greens, beetroot) feeds NO via the nitrate–nitrite–NO pathway, partially independent of NOS. The combined effect of citrulline plus nitrate appears additive in some trials (e.g., the Arribalzaga and Domínguez-Balmaseda triathlete trials), suggesting synergy.

Potential Risks & Side Effects

A dedicated search for the L-Citrulline side effect profile was conducted across drug reference sources (drugs.com, NIH MedlinePlus, Mayo Clinic, ConsumerLab, Examine), the published trial literature, and manufacturer safety data prior to this section.

Medium 🟥 🟥

Hypotension with Antihypertensive Medications

L-Citrulline lowers blood pressure modestly via NO-mediated vasodilation. In adults already taking antihypertensive medications — especially nitrates (e.g., nitroglycerin, isosorbide mononitrate), PDE5 inhibitors (sildenafil, tadalafil, vardenafil), calcium channel blockers (drugs that relax vascular smooth muscle by blocking calcium entry, e.g., amlodipine, nifedipine), ACE inhibitors (angiotensin-converting enzyme inhibitors, e.g., lisinopril), angiotensin receptor blockers (ARBs, e.g., losartan, valsartan), beta blockers (drugs that slow heart rate and reduce cardiac output by blocking adrenergic β-receptors), and diuretics (drugs that lower blood pressure by increasing urine output and reducing fluid volume) — the additive effect can produce symptomatic hypotension (low blood pressure causing dizziness, fainting, or falls). ConsumerLab specifically flags this as the most clinically relevant interaction in healthy older adults.

Magnitude: −4 to −10 mmHg additional systolic reduction on top of existing therapy in some cases; risk of symptomatic hypotension primarily in those with already low or well-controlled blood pressure.

Cold Sore (Herpes Simplex) and Canker Sore Reactivation in Susceptible Individuals

L-Citrulline raises systemic L-arginine, and L-arginine is a known reactivation trigger for herpes simplex virus (HSV-1, the virus most commonly causing cold sores; and HSV-2, the virus more commonly causing genital lesions) in seropositive individuals. Andrew Huberman has publicly noted this risk in his commentary on citrulline supplementation, and case reports describe cold-sore and canker-sore (aphthous ulcer) reactivation in sensitive users. Mechanistically, HSV replication requires arginine, while lysine competes with arginine at the cellular level — the rationale for the long-standing low-arginine, high-lysine prophylactic diets used by some HSV-positive adults.

Magnitude: Anecdotal and case-report level; incidence not quantified in supplementation trials, which generally do not screen for HSV status.

Low 🟥

Gastrointestinal Effects

Nausea, dyspepsia, gas, bloating, heartburn, and loose stools are reported in a minority of users at doses ≥6 g and especially at ≥10 g. Citrulline malate (which contains malic acid) can be acidic and is more often associated with stomach upset than free L-Citrulline base. Effects are dose-dependent and improve with dose reduction, with food, or by switching to free L-Citrulline.

Magnitude: Reported in approximately 5–15% of subjects in higher-dose trials (≥6 g); mild and self-limited in most cases.

Headache

Mild headache is occasionally reported with single doses of 6–10 g, presumably reflecting peripheral vasodilation. Generally mild and self-limited; resolves on dose reduction or discontinuation.

Magnitude: Reported in approximately 3–8% of trial subjects at higher doses; mild.

Lightheadedness or Dizziness

Mild lightheadedness can occur, particularly when starting therapy or with concurrent antihypertensive use, reflecting the same vasodilatory mechanism that drives the blood pressure effect.

Magnitude: Reported in approximately 2–5% of trial subjects; usually transient.

Speculative 🟨

Hypotension During Surgery

Concern has been raised that perioperative L-Citrulline use could compound anesthesia-induced hypotension. No specific case reports or trials have documented this, but the mechanism is plausible enough that elective discontinuation 1–2 weeks before scheduled surgery is the standard precautionary practice for nitric oxide–donor and arginine-pathway supplements.

Pregnancy and Lactation Safety

Direct interventional safety data for L-Citrulline during human pregnancy are limited; the AGREE trial in pregnant women is currently recruiting. Animal data and the parallel L-arginine literature do not raise significant red flags, but precautionary avoidance outside controlled trial contexts is the default.

Theoretical Concern in Citrullinemia and Argininosuccinic Aciduria

In rare inherited urea cycle disorders where citrulline accumulates upstream of a deficient enzyme — citrullinemia type I (ASS deficiency) and argininosuccinic aciduria (ASL deficiency) — supplemental L-Citrulline is contraindicated and could worsen the metabolic abnormality. Routine adult use does not encounter these populations, but a confirmed diagnosis or strong family history should prompt avoidance.

Theoretical Concern in Cancer

Some cancer cells exploit the L-arginine pathway and ADMA balance for proliferation. Whether supplemental L-Citrulline would meaningfully alter clinical cancer trajectory is unknown; mechanistic concern is theoretical only and is not supported by clinical evidence in either direction.

Risk-Modifying Factors

  • Genetic polymorphisms: Confirmed inherited urea cycle disorders — citrullinemia type I (ASS deficiency) and argininosuccinic aciduria (ASL deficiency) — are absolute contraindications because supplemental L-Citrulline could worsen the metabolic abnormality. Beyond these rare conditions, common eNOS polymorphisms (e.g., Glu298Asp) may modulate vasodilatory responsiveness and indirectly affect hypotension risk in those on antihypertensive therapy. Routine genotyping is not warranted for most users.

  • Concurrent antihypertensive therapy: Nitrates, PDE5 inhibitors, calcium channel blockers, ACE inhibitors, ARBs, beta blockers, and diuretics all amplify the blood pressure–lowering effect; lower starting doses and clinical supervision are appropriate.

  • Baseline blood pressure: Adults with blood pressure already at or below target (e.g., systolic <115 mmHg) or with frequent orthostatic hypotension (a drop in blood pressure when standing up that causes dizziness) are at higher risk for symptomatic hypotension.

  • Herpes simplex virus serostatus: Adults with frequent cold sores, canker sores, or genital herpes outbreaks may be more susceptible to reactivation; lysine co-supplementation or simply avoidance may be preferable in this subset.

  • Pre-existing health conditions: Severe liver disease alters urea cycle handling; advanced kidney disease may alter renal conversion of citrulline to arginine; both warrant clinical caution. Confirmed urea cycle disorders of the citrullinemia type are an absolute contraindication.

  • Sex differences: Females may show smaller exercise blood-flow responses; data are limited and sex-specific safety differences are not clearly characterized.

  • Age-related considerations: Older adults are more likely to be on polypharmacy (multiple antihypertensives, nitrates, PDE5 inhibitors); the additive blood pressure effect has a greater consequence in this group. Lower starting doses are appropriate.

  • Surgical context: Discontinuation 1–2 weeks before elective surgery avoids potential additive hypotension under anesthesia.

  • Pregnancy and lactation: Direct interventional data are limited; avoidance outside clinical trial contexts is the default.

Key Interactions & Contraindications

  • Nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate): additive vasodilation can produce severe hypotension. Severity: avoid combination; absolute contraindication with high-dose nitrate regimens.

  • Phosphodiesterase type 5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil): additive cGMP-mediated vasodilation; severe hypotension reported with PDE5 inhibitors plus nitrates and a similar concern attaches to PDE5 inhibitors plus citrulline. Severity: caution; monitor for hypotension, especially with on-demand ED use.

  • Antihypertensive medications (ACE inhibitors such as lisinopril, ARBs such as losartan, calcium channel blockers such as amlodipine, beta blockers, diuretics): additive blood pressure reduction. Severity: caution; lower citrulline starting doses and monitor blood pressure; dose adjustment of antihypertensives may be needed.

  • Anticoagulants and antiplatelet agents (warfarin, apixaban, rivaroxaban, aspirin, clopidogrel): no major direct interaction documented, but the NO-mediated antiplatelet effect could be additive with antiplatelet drugs in theory. Severity: caution rather than avoidance.

  • Over-the-counter medications (OTC, available without a prescription; including OTC nasal decongestants such as pseudoephedrine and phenylephrine, OTC stimulants): sympathomimetic decongestants can raise blood pressure and partially offset citrulline’s effect. Severity: mild interaction; clinical relevance limited.

  • L-arginine, L-ornithine, and other NO-pathway amino acids: additive substrate effect on NO synthesis. Severity: mild caution; combined regimens are common in cardiovascular protocols and are sometimes intentional.

  • Beetroot juice and dietary nitrate, organic nitrites, and nitric-oxide–donor supplements: additive NO generation through partly independent pathways. Severity: caution in adults with low baseline blood pressure; intentional pairing is common in athletic protocols.

  • Lysine supplementation: lysine competes with arginine for cellular uptake and is used to suppress HSV reactivation; concurrent low-dose lysine may partially offset arginine-related cold-sore risk in susceptible users. Severity: not adverse; potentially beneficial co-administration.

  • Anesthesia and perioperative drugs: vasodilators, volatile anesthetics, and induction agents can cause hypotension that may be amplified by citrulline. Severity: discontinue 1–2 weeks before scheduled surgery.

  • Supplements with additive blood-pressure–lowering or NO-related effects: beetroot extract, hawthorn, garlic extract, Ginkgo biloba (though primarily a platelet effect), CoQ10, taurine, magnesium, and high-dose hibiscus tea may all contribute; combined regimens warrant blood pressure monitoring.

  • Other interventions: sauna and heat exposure, intense exercise, and alcohol all transiently lower blood pressure and may compound citrulline’s effect during the same window.

  • Populations to avoid: confirmed urea cycle disorders of the citrullinemia type (ASS deficiency, ASL deficiency); concurrent nitrate therapy for angina; current PDE5 inhibitor on-demand or daily use without clinical supervision; recent myocardial infarction (<30 days) or acute decompensated heart failure (NYHA Class IV — the New York Heart Association’s most severe heart failure category, with symptoms at rest); symptomatic orthostatic hypotension; pregnancy and lactation outside clinical trials; severe hepatic impairment (Child-Pugh Class C — the most severe class on the Child-Pugh score for liver disease severity); advanced kidney disease (eGFR <30 mL/min/1.73m²; eGFR is the estimated glomerular filtration rate, a measure of kidney function); HSV-1 or HSV-2 with frequent recurrent outbreaks (relative caution); planned surgery within 1–2 weeks.

Risk Mitigation Strategies

  • Screen for nitrate and PDE5 inhibitor use before starting: the most consequential safety check is to confirm the user is not on prescription nitrates for angina or on PDE5 inhibitors for ED or pulmonary hypertension; the additive vasodilatory effect can produce severe symptomatic hypotension. Mitigates: severe hypotension.

  • Start at the low end of the dose range (1–3 g) and titrate up as tolerated: standard practice is to begin at 3 g/day in healthy adults and 1–1.5 g/day in older adults or those on antihypertensive therapy, increasing to 6 g/day over 1–2 weeks if tolerated. Mitigates: hypotension, GI effects.

  • Monitor blood pressure during initiation and titration: measure resting blood pressure at baseline and at 1–2 weeks of supplementation, especially in adults already on antihypertensive medications, to detect additive effects early. Mitigates: symptomatic hypotension and need for antihypertensive dose adjustment.

  • Use free L-Citrulline rather than citrulline malate for users with sensitive stomachs or heartburn: the malic-acid component of citrulline malate is a frequent driver of GI complaints; switching to free L-Citrulline often resolves these without losing efficacy. Mitigates: GI effects, heartburn.

  • Consider concurrent low-dose lysine in HSV-1– or HSV-2–positive users: lysine competes with arginine at the cellular level; 500–1,000 mg/day may help reduce arginine-driven HSV reactivation in susceptible adults, though efficacy is modest. Mitigates: cold sore and canker sore reactivation.

  • Discontinue 1–2 weeks before elective surgery: standard precaution for nitric-oxide–donor and amino acid supplements that may compound anesthesia-related hypotension. Mitigates: perioperative hypotension.

  • Source from third-party–tested, reputable brands using Kyowa or Ajinomoto raw material: ConsumerLab testing has identified label-accuracy and heavy metal contamination issues with some products; pharmaceutical-grade raw material reduces purity-related risks. Mitigates: contamination, heavy metals, label inaccuracy.

  • Avoid combination with high-dose dietary nitrate (concentrated beetroot shots) in adults with low baseline blood pressure: the additive NO effect can drop blood pressure further than intended in already-normotensive or low-normal adults; intentional pairing is reasonable only when the intent is greater blood pressure reduction or athletic performance under monitoring. Mitigates: excessive hypotension.

  • Reassess after 4–8 weeks of consistent dosing: if no clear blood pressure or subjective benefit is observed at adequate dose, the underlying assumption (substrate-limited NO synthesis) is unlikely to apply; reassess rather than continuing indefinitely. Mitigates: prolonged unnecessary exposure.

Therapeutic Protocol

L-Citrulline protocols vary by indication; the following reflects typical practice in evidence-based integrative-cardiology and sports-nutrition contexts, drawing on Mark Houston and the integrative-cardiology hypertension community for the blood pressure dosing pattern (formalized in the 2025 Luo meta-analysis and the earlier 2018 Mirenayat synthesis) and on Eric Trexler and the sports-nutrition research community (later echoed in the 2019 Trexler and 2020 Rhim meta-analyses) for the acute pre-exercise pattern.

  • Cardiovascular dosing (blood pressure, vascular function): 3–6 g of free L-Citrulline once daily, in the morning or evening, for 4–8 weeks before reassessing — the protocol most consistently associated with blood pressure reductions in the Luo and Mirenayat meta-analyses; some protocols use 1.5 g twice daily.

  • Erectile function dosing: 1.5 g once daily for at least 1 month, on the schedule of the Cormio 2011 trial; some integrative practitioners pair this with low-dose L-arginine, Pinus pinaster (Pycnogenol), or transresveratrol based on small adjunct trials.

  • Pre-exercise dosing (strength, power, recovery): 6–8 g of L-Citrulline (or 8 g of citrulline malate, which contains ~5.3 g of citrulline) taken 60 minutes before training — the schedule used in the majority of the strength and recovery RCTs included in the Trexler and Rhim meta-analyses.

  • Best time of day: morning or evening for cardiovascular use; 60 minutes pre-training for performance use. Bedtime dosing may produce mild diuresis or interrupt sleep in some users.

  • Half-life and dosing strategy: free L-Citrulline plasma half-life is short (a few hours); the downstream L-arginine elevation peaks at ~1 hour and persists for several hours. For sustained vascular benefit, daily dosing matters more than precise timing. For pre-exercise, the 60-minute pre-load is matched to the L-arginine peak.

  • Single vs. split dosing: for cardiovascular use, both single (3–6 g once daily) and split (1.5–3 g twice daily) regimens have been used in trials; both work. For pre-exercise use, a single pre-workout dose is standard.

  • Form considerations: free L-Citrulline (the L-isomer) is the standard form. Citrulline malate combines L-Citrulline with malic acid in either a 1:1 or 2:1 ratio (label specification varies and is not always declared); the malate component contributes acidity and a small theoretical role in the Krebs cycle but does not change the core mechanism. Free L-Citrulline is generally preferred for cardiovascular use; citrulline malate is more common in pre-workout formulations. D-Citrulline is not the active isomer.

  • Genetic considerations: routine genotyping is not standard; the relevant context is exclusion of inherited urea cycle disorders (citrullinemia types) before any therapeutic-dose use. Pharmacogenetically relevant variants such as APOE4 (a lipid-transport gene variant linked to cardiovascular and neurodegenerative risk), MTHFR (a folate-metabolism enzyme variant influencing homocysteine), and COMT (catechol-O-methyltransferase, an enzyme that breaks down catecholamines and influences vascular tone) may modulate the cardiovascular context but do not directly alter L-Citrulline pharmacokinetics.

  • Sex-based considerations: smaller exercise-blood-flow effects have been reported in older women than in older men in some trials; conservative dosing (3 g) is reasonable.

  • Age considerations: for adults ≥60 with hypertension or polypharmacy, start at 1–1.5 g/day and titrate upward over 2–4 weeks while monitoring blood pressure. Cardiovascular benefit is most relevant in this group.

  • Baseline biomarkers: resting blood pressure and (if available) plasma L-arginine and ADMA are useful baseline measurements for cardiovascular use; they are not strictly required.

  • Pre-existing health conditions: absolute avoidance with citrullinemia and concurrent prescription nitrate therapy; caution with PDE5 inhibitors, multi-drug antihypertensive regimens, advanced kidney or liver disease.

Discontinuation & Cycling

  • Duration: L-Citrulline can be used short-term (single pre-workout doses), medium-term (4–8 weeks for blood pressure assessment), or chronically. Most controlled trials are weeks to a few months; long-term (years) data are sparse.

  • Withdrawal effects: no addictive or withdrawal syndrome is recognized. Blood pressure and exercise effects fade within days to weeks of stopping.

  • Tapering protocol: not required from the supplement side; pharmacology does not necessitate a taper. Adults whose antihypertensive medication has been adjusted downward in response to citrulline may need their prescriber to revisit antihypertensive dosing if citrulline is discontinued.

  • Cycling for tolerance or efficacy: tachyphylaxis (loss of effect over time) has not been clearly demonstrated for L-Citrulline. Some sports-nutrition protocols cycle 4–8 weeks on / 1–2 weeks off, mainly to verify ongoing effect rather than to address tolerance. Continuous use is acceptable for cardiovascular indications.

  • Reassessment of indication: if used daily for 8 weeks at adequate dose without measurable blood pressure or subjective benefit, the substrate-limited assumption is unlikely to apply; reassess rather than escalating dose.

Sourcing and Quality

  • Form: free L-Citrulline (the L-isomer) in capsule, tablet, or powder form is the standard. Pharmaceutical-grade material — most commonly Kyowa-Hakko or Ajinomoto raw material — is the de facto purity standard. D-Citrulline and racemic mixtures should not be substituted.

  • Citrulline malate caveats: citrulline malate is a 1:1 or 2:1 salt of L-Citrulline with malic acid; the label “citrulline malate” alone often does not specify the ratio, and the actual L-Citrulline content can therefore vary substantially between products. ConsumerLab and Examine both note that label accuracy is a recurring issue.

  • Purity and certifications: prefer products with USP, NSF Certified for Sport, ConsumerLab Top Pick status, or Informed-Sport certification. Third-party testing for heavy metals (lead, cadmium, arsenic) and label-claim verification reduces real-world risk.

  • Dose accuracy: label claim should match content; ConsumerLab has reported discrepancies in some L-Citrulline products. Capsules are most often sold at 750 mg or 1,000 mg; powder forms allow flexible dosing.

  • Excipients: prefer products with minimal excipients; verify against unnecessary fillers, artificial colors, and unjustified additives. Some pre-workout formulations bury L-Citrulline within proprietary blends and may not deliver an effective dose.

  • Reputable brands: brands cited by integrative and sports-nutrition communities and identified by ConsumerLab include Doctor’s Best, NOW Foods, Pure Encapsulations, Thorne, Designs for Health, Life Extension, Jarrow Formulas, and Klean Athlete; Kyowa Quality (KQ-branded) raw material is a recognized purity benchmark. Third-party–tested products are preferred where available.

  • Cost benchmark: L-Citrulline is moderately priced (typically $0.10–$0.30 per gram for reputable bulk-powder brands; capsule forms are more expensive per gram).

Practical Considerations

  • Time to effect: plasma L-arginine peaks 1 hour after an oral dose; pre-exercise effects are observed 60 minutes after dosing. Blood pressure effects emerge over 1–2 weeks of consistent daily use and stabilize by 4–8 weeks. Erection-quality effects in mild ED are described after 1 month of daily dosing in the Cormio trial.

  • Common pitfalls: combining with prescription nitrates or PDE5 inhibitors without supervision (the single most consequential mistake); using citrulline malate without recognizing that the L-Citrulline content is only 50–67% of the labeled “citrulline malate” weight; under-dosing within a proprietary pre-workout blend; expecting strong endurance benefits in young trained adults (unsupported by meta-analyses); ignoring the cold-sore reactivation risk in HSV-positive users; choosing unverified brands with label-accuracy or heavy metal issues.

  • Regulatory status: in the United States, L-Citrulline is sold as a dietary supplement under DSHEA (the Dietary Supplement Health and Education Act, the U.S. law governing supplement marketing and labeling). The FDA does not regulate dose or purity directly; quality varies, and third-party–tested products are preferred. In some countries, citrulline malate (Stimol) has been marketed as a prescription product for asthenia.

  • Cost and accessibility: widely available without prescription; inexpensive in bulk-powder form. No exceptional accessibility issues outside of regulatory variation across countries.

Interaction with Foundational Habits

  • Sleep: Indirect, mostly neutral interaction. L-Citrulline does not directly affect sleep onset or architecture. Late-evening dosing produces no consistent benefit or harm in trial data; some users report a mild diuretic effect that may interrupt sleep, which is the rationale for morning or pre-dinner dosing rather than bedtime use.

  • Nutrition: Direct interaction through both diet content and timing. A diet rich in dietary nitrate (leafy greens, beetroot) acts on the parallel nitrate–nitrite–NO pathway and can be additive with citrulline. Watermelon is a natural food source of L-Citrulline (~0.4 g per kilogram of red flesh), and watermelon-based citrulline trials show comparable blood pressure effects to capsule forms. In practice: trial data show no clinically meaningful difference between dosing with or without food; co-consumption with leafy greens or beetroot is associated with additive effects in some trials; adequate dietary protein supports endogenous arginine supply.

  • Exercise: Direct interaction with potentiating potential. The 2023 Xie et al. meta-analysis suggests combined exercise plus citrulline produces modest additive benefits on lean mass and lower-limb function in older adults. The 2019 Trexler and 2020 Rhim meta-analyses support a small acute-performance and recovery effect. In trial protocols, performance-oriented dosing is typically given 60 minutes before training; the cardiovascular benefit from chronic dosing is independent of training but compounds with regular aerobic exercise, which itself improves endothelial function.

  • Stress management: Indirect, mostly neutral interaction. Acute psychological stress raises ADMA and impairs eNOS function; chronic stress is associated with worse endothelial function and higher blood pressure. Effective stress management (sleep, meditation, breathwork, social connection, exercise) supports the same NO biology that citrulline supports through substrate provision. The two are complementary; citrulline does not substitute for stress-management practice.

Monitoring Protocol & Defining Success

Baseline testing establishes a reference point before initiating L-Citrulline, particularly for users targeting blood pressure or for those with cardiovascular risk; ongoing monitoring is minimal for short-term pre-workout use but more relevant for chronic cardiovascular dosing.

Ongoing monitoring cadence: home blood pressure logs (twice weekly) for the first 4 weeks of cardiovascular use, then monthly thereafter; clinical blood pressure check at 1–2 weeks if on antihypertensive therapy; symptom log for orthostatic hypotension (dizziness on standing) during initiation.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Resting blood pressure <120/80 mmHg Primary outcome for cardiovascular use Average of 2–3 morning readings over 1 week; track baseline and at 4–8 weeks; conventional reference is <130/80 mmHg
Plasma L-arginine 60–100 µmol/L Confirms substrate availability for NO synthesis Specialty test; rarely needed in routine practice; useful when response is unclear
ADMA (asymmetric dimethylarginine) <0.5 µmol/L Reflects endogenous NOS inhibition and vascular aging Specialty test; conventional reference range varies by lab; relevant for vascular-aging research
L-arginine/ADMA ratio >100 Composite indicator of NO substrate availability Specialty test; integrates the two measures above
Endothelial function (FMD) >7% brachial artery dilation Direct measure of NO-mediated vascular function FMD is flow-mediated dilation; specialty test; requires ultrasound; mainly research and integrative-cardiology settings
High-sensitivity CRP (hs-CRP) <1.0 mg/L Reflects systemic inflammation that worsens endothelial NO biology Conventional reference <3.0 mg/L; functional medicine targets <1.0 mg/L
BUN and creatinine, with eGFR BUN 8–18 mg/dL; eGFR ≥90 mL/min/1.73m² Renal function (citrulline–arginine conversion happens in kidney) BUN is blood urea nitrogen; eGFR is the estimated glomerular filtration rate, a measure of kidney function; conventional reference BUN 7–20 mg/dL; functional medicine targets the lower half; relevant in older adults and chronic kidney disease
Plasma ammonia <50 µmol/L Safety screen given urea cycle role Mainly relevant in suspected urea cycle dysfunction; not routine

Qualitative markers to track:

  • Home blood pressure trend (twice weekly during the first month)
  • Subjective exercise tolerance and recovery quality
  • Erection quality and frequency (for ED indication)
  • Cold sore or canker sore frequency in HSV-positive users
  • Lightheadedness or dizziness on standing during initiation
  • Heartburn or GI symptoms with citrulline malate
  • Subjective energy and exercise capacity in older adults

Emerging Research

  • L-Citrulline in HFpEF: Novel Approaches for Improving Vascular Function in Veterans With HFpEF (NCT06312748) — a 90-participant Phase 1 trial comparing L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin (with placebos) on physical capacity and vascular function in heart failure with preserved ejection fraction.

  • L-Citrulline in deployment-related asthma: Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation (NCT05259904) — a 75-participant Phase 2 trial of L-Citrulline as add-on therapy in obese asthmatics with low fractional exhaled nitric oxide (FeNO, the airway NO biomarker), building on Fernando Holguin’s earlier work showing that 15 g/day of L-Citrulline improved asthma control and lung function in the obese late-onset phenotype.

  • L-Citrulline for severely ill children: EChiLiBRiST clinical trial 2 (NCT06426147) — a recruiting trial with an estimated enrollment of 2,200 hospitalized children in Mozambique and Ethiopia (an ~888-child sub-cohort of moderate-to-high risk participants identified via a sTREM-1 point-of-care test will be randomized to L-Citrulline) comparing 200–300 mg/kg/day of oral L-Citrulline syrup versus placebo for 28 days for adverse outcomes including mortality.

  • L-Citrulline in pregnancy: L-ArGinine to pRevent advErse pRegnancy outcomEs (AGREE, NCT05934318) — a 2,960-participant trial in malaria-endemic areas of Kenya comparing twice-daily L-Citrulline supplementation with placebo for adverse pregnancy outcomes (pregnancy loss, preterm birth, low birth weight, small for gestational age, neonatal mortality).

  • Intravenous L-Citrulline for sickle cell vaso-occlusive crisis: Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease (NCT06635902) — a Phase 2 trial of 99 hospitalized patients evaluating IV citrulline for acute pain duration and safety.

  • L-Citrulline in malnourished COPD: Oral Citrulline Supplementation in COPD Patients With Malnutrition (NCT06212765) — a 60-participant Phase 3 trial of 10 g/day of L-Citrulline for 45 days in malnourished severe chronic obstructive pulmonary disease (COPD, a progressive lung disease that causes airflow obstruction and breathing difficulty) patients, with fat-free mass as the primary endpoint.

  • Vascular-aging and endothelial function: future research areas include whether long-term L-Citrulline supplementation alters endothelial function, arterial stiffness, and downstream cardiovascular events. The Luo et al. 2025 arterial stiffness meta-analysis is a recent synthesis pointing to modest improvements in flow-mediated dilation but mixed effects on pulse wave velocity, with calls for larger, longer trials in midlife adults at risk.

  • Long-term safety and combinations: the largest evidence gaps are multi-year safety data and head-to-head comparisons with dietary nitrate (beetroot) and L-arginine. Future research areas include longer trials in older adults, sex-stratified analyses, and combination protocols to define when citrulline plus arginine, citrulline plus nitrate, or citrulline plus exercise produce additive or substituted effects.

Conclusion

L-Citrulline occupies a useful but bounded position in the supplement landscape: a non-protein amino acid that, when supplemented, reliably raises L-arginine and supports nitric oxide signaling, with a small-but-real effect on resting blood pressure in middle-aged and older adults, a meaningful effect on erection quality in men with mild erectile dysfunction at modest dose, and a small effect on perceived exertion and post-exercise muscle soreness. The most consistent benefit appears in adults with some degree of endothelial dysfunction; effects in healthy young adults are smaller and less consistent.

The safety profile is favorable for healthy adults at moderate doses, with three caveats worth careful screening. Concurrent prescription nitrate medications for angina and erectile-dysfunction medications such as sildenafil create a clinically important additive vessel-relaxing effect that requires medical supervision. Adults with frequent cold sores or canker sores may experience reactivation owing to the rise in arginine. And rare inherited disorders that disrupt the body’s nitrogen-handling cycle are an absolute reason to avoid the supplement, although these are rare in adult populations.

For health- and longevity-oriented adults, the practical signal is that L-Citrulline is a tool with a narrow but real edge for blood pressure support and vascular function in midlife and beyond, provided medication and quality screens are passed. It is not a foundational longevity supplement, and the underlying biology that links nitric oxide to vascular aging is more reliably influenced by exercise, diet, weight management, and sleep than by oral substrate provision alone.

Top - Benefits - Risks - Protocol